Neuren Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is January - December.

Millions AUD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	149.06	142.04	157.08	0.18	-7.79	-9.19
Depreciation & Amortization	0.02	0.02	0.02	0.01	0.01	0.01
Loss (Gain) From Sale of Investments	0.96	-3.59	1.53	0.7	-	-
Stock-Based Compensation	0.98	1.23	2.93	1.99	0.84	0.39
Other Operating Activities	5.26	10.44	0.14	0.18	-0.4	0.72
Change in Accounts Receivable	-6.13	-157.59	-13.11	0.19	-2.51	-0.2
Change in Accounts Payable	2.71	-	-	0.34	-0.11	0.19
Change in Income Taxes	-15.28	-3.83	36.35	-	-	-
Operating Cash Flow	137.57	-11.27	184.93	3.6	-9.97	-8.08
Operating Cash Flow Growth	15.11%	-	5038.23%	-	-	-
Capital Expenditures	-0.01	-0.01	-0.04	-0.02	-0.01	-0.01
Investment in Securities	-82.27	4.14	-211.45	-	-	-
Investing Cash Flow	-82.28	4.13	-211.49	-0.02	-0.01	-0.01
Issuance of Common Stock	1.38	1.66	3.64	-	23.28	20.22
Repurchase of Common Stock	-50	-10.43	-	-	-	-
Other Financing Activities	-0.02	-0.01	-0.02	-0	-1.11	-1.08
Financing Cash Flow	-48.63	-8.78	3.62	-0	22.18	19.14
Foreign Exchange Rate Adjustments	-3.32	1.97	-0.15	-0.18	0.4	-0.71
Net Cash Flow	3.34	-13.94	-23.09	3.4	12.6	10.34
Free Cash Flow	137.56	-11.28	184.89	3.58	-9.98	-8.08
Free Cash Flow Growth	15.13%	-	5064.39%	-	-	-
Free Cash Flow Margin	62.85%	-5.20%	79.71%	23.22%	-312.17%	-1127.48%
Free Cash Flow Per Share	1.06	-0.09	1.41	0.03	-0.08	-0.08
Cash Income Tax Paid	50.03	37.22	-0.88	-1.39	-2.52	-0.49
Levered Free Cash Flow	109.15	-42.25	152.97	2.59	-6.76	-5.12
Unlevered Free Cash Flow	109.15	-42.25	152.97	2.59	-6.76	-5.12
Change in Working Capital	-18.7	-161.42	23.24	0.53	-2.62	-0.01

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.